

**Sun Pharmaceutical Industries Limited**

SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**July 16, 2021**

**National Stock Exchange of India Limited,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai- 400 051

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrip Symbol: SUNPHARMA**

**Scrip Code: 524715**

Sub: Press Release

Dear Sir / Madam,

We are pleased to enclose herewith our Press Release relating to Earnings Call for financial results for the first quarter ending June 30, 2021, which we shall be releasing after sending this letter to you.

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For **Sun Pharmaceutical Industries Limited**

**Ashok I. Bhuta**  
**Compliance Officer**  
Enclosed: As above

## Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
www.sunpharma.com



**FOR IMMEDIATE RELEASE**

### **Sun Pharma to announce first quarter results on July 30, 2021**

July 16, 2021, Mumbai: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) will announce results for the first quarter ending June 30, 2021 on July 30, 2021. These results will also be available on the Company website, [www.sunpharma.com](http://www.sunpharma.com).

#### **Earnings call (06.30 pm IST, July 30, 2021)**

The Company will conduct an hour long call at 06.30 pm IST on July 30, 2021 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please pre-register yourself on below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, [www.sunpharma.com](http://www.sunpharma.com). A transcript of this conference call will also be available on the website.

#### **Summary of events**

| <b>Event</b>                                  | <b>Date and time</b>                | <b>Telephone number/ website</b>   |
|---|-------------------------------------|--|
| Earnings release                              | July 30, 2021                       | <a href="http://www.sunpharma.com">www.sunpharma.com</a>   |
| Earnings conference call                      | 06.30 pm IST,<br>July 30, 2021      | Universal Number: +91 22 5064 1325<br><br>Via audio webcast, details of which will be made available on <a href="http://www.sunpharma.com">www.sunpharma.com</a>   |
| Pre-registration details (to avoid wait time) |                                     | Click here for <a href="#">DiamondPassRegistration</a>   |
| Replay of conference call                     | July 30, 2021 to<br>August 06, 2021 | India: +91 22 7194 5757<br>India: +91 22 6663 5757<br><br>Code: 93696<br><br>Via audio webcast playback, details of which will be made available on <a href="http://www.sunpharma.com">www.sunpharma.com</a> |

## Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
CIN: L24230GJ1993PLC019050  
[www.sunpharma.com](http://www.sunpharma.com)



### **Disclaimer:**

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

### **About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):**

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) & follow us on Twitter @SunPharma\_Live

### **Contacts:**

#### **Investors:**

Nimish Desai  
Tel +91 22 4324 4324, Xtn 2778  
Tel Direct +91 22 4324 2778  
Mobile +91-98203 30182  
E mail [nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

#### **Media:**

Gaurav Chugh  
Tel +91 22 4324 4324, Xtn 5373  
Tel Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E mail [Gaurav.chugh@sunpharma.com](mailto:Gaurav.chugh@sunpharma.com)